Imagion Biosystems Ltd. · ASX:IBX
Imagion Biosystems — Investor Presentation (May 2019)
16 slides from Imagion Biosystems's investor presentation, May 20, 2019
Slide 1: MagSense Technology: Early Detection of Cancer Through Targeted Imaging
® B I O S Y S T E M S MagSense™ Technology Early Detection of Cancer Through Targeted Imaging ASX:IBX
Slide 2: Disclaimer
DISCLAIMER This investor presentation (Presentation) has been prepared by Imagion Biosystems Limited (Imagion or the Company). This presentation does not constitute or form part of, and should not be construed as, an offer, solicitation or invitation to subscribe for, underwrite or otherwise acquire
Slide 3: 1 in 3 People are affected by Cancer
1 in 3 People are affected by Cancer “Early detection of many diseases, particularly cancers, is key to successful treatment.” “Despite technical advances in many areas of diagnostic radiology, the detection and imaging of human cancer remains poor. “ Chemical Reviews 2015 Nanoparticles in Medicine
Slide 4: The Benefits of Early Detection
T H E B E N E F I T S O F E A R LY D E T E C T I O N Cost / Benefit ratio for early diagnosis provides better value than most drugs IMPROVEMENT IN 5-YEAR SURVIVAL RATE… …using drugs …with early diagnosis Early diagnosis To bring a drug to results in: market: • 2-4x less cost • $2.8 billion • Lower d
Slide 5: Improving Diagnosis in Cancer: Multiple Clinical Targets
IMPROVING DIAGNOSIS IN CANCER Imagion has a platform technology that can improve diagnosis for many common cancers BREAST CANCER • Staging of metastatic HER2+ breast cancer eliminates Multiple Clinical Targets lymphadenectomy for 50% of patients • Detection of primary tumor would eliminate uncertain
Slide 6: Clear Unmet Medical Need
CLEAR UNMET MEDICAL NEED 50 years since last new imaging technology was introduced Current technologies: ꟷ Identify a “region of interest” ꟷ Expose patients to radiation ꟷ Require invasive biopsies to confirm ꟷ Result in unnecessary biopsies IMAGIONBIOSYSTEMS.COM | 6
Slide 7: A New Way to Detect Cancer
A N E W WAY TO D E T E C T C A N C E R MagSense™ Technology will transform cancer diagnosis Better sensitivity leads to earlier detection & more treatment options MORE SENSITIVE Better sensitivity than other imaging methods Mammogram Enabling earlier detection and treatment CT Scan SPECIFIC Function
Slide 8: How It Works
HOW IT WORKS Bio-safe magnetic nanoparticles are attracted to the tumor and detected • Nanoparticles, specific for the cancer, bind to tumor cells • Nanoparticles demagnetize or “relax” after exposure to a low magnetic field • Nanoparticles attached to cancer cells “relax” more slowly than particles
Slide 9: De-risking the Approval Process
D E R I S K I N G T H E A P P ROVA L P RO C E S S MagSense uses proven components & known principles KNOWN MATERIALS Iron oxide is already in use as contrast agent Antibodies are standard for therapeutics & diagnostics Safety profile has been affirmed as low risk by FDA Cancer specific nanoparticle
Slide 10: Compelling Business Model
COMPELLING BUSINESS MODEL Proprietary consumable drives growth & profitability PRINTER / INK ONE INSTRUMENT MANY TESTS REVENUE MODEL HER2 Breast Ovarian 35% capacity utilization Cancer Cancer $2.2 million annual revenue per instrument Prostate Lung Cancer Cancer Revenue through $500K Capital Sale $1
Slide 11: Strong R&D Pipeline
STRONG R&D PIPELINE Product Applications Under Development Research Pre-Clinical Clinical Design In Vitro Animal Models Tox/Safety Early Feasibility Pivotal Metastatic HER2 Breast Cancer Invasive Breast • The basic nanoparticle formulation is consistent MagSense Pipeline Cancer across different canc
Slide 12: Milestones and Valuation Drivers
M I L E S TO N E S A N D VA L U AT I O N D R I V E R S Indicative development timeline and key inflection points* v Toxicology Study provides safety profile and clears path to product manufacturing for use in humans. Contract v Clearance by regulatory authority and clinical site for First-In- Manufa
Slide 13: Strategic Plan
S T R AT E G I C P L A N Path to future products & value STAGING TUMOR MRI TREATMENT DOCTORS DETECTION & BREAST CANCER DETECTION CONTRAST MONITORING OFFICE THERAPY Reduce unnecessary Breast, prostate, lung Safer alternative to Monitor tumor size Hand-held MagSense Provide both surgery & ovarian curr
Slide 14: Experienced Team
EXPERIENCED TEAM Core Strengths of Team JOHN HAZLE PHD JOVANKA NAUMOSKA v Bringing medical devices to ROBERT PROULX CHAIRMAN & CEO NON EXEC DIRECTOR MICHAEL HARSH NON EXEC DIRECTOR NON EXEC DIR & COSEC BRONWYN LE GRICE NON EXEC DIRECTOR • Operationally oriented • Board certified in medical • Former
Slide 15: Investment Highlights
INVESTMENT HIGHLIGHTS LARGE OPPORTUNITY UNIQUE TECHNOLOGY $100B cancer diagnostic market New form of medical imaging Growing 7% annually Molecularly specific & non-invasive Medical imaging commands largest share More sensitive than current methods Under-addressed need for early diagnosis Protected b
Slide 16: Imagion Biosystems
® B I O S Y S T E M S IMAGION BIOSYSTEMS www.imagionbiosystems.com
Imagion Biosystems — Investor Presentation (May 2019) on 6ix